0001628280-23-019588.txt : 20230524 0001628280-23-019588.hdr.sgml : 20230524 20230524160654 ACCESSION NUMBER: 0001628280-23-019588 CONFORMED SUBMISSION TYPE: 8-K PUBLIC DOCUMENT COUNT: 13 CONFORMED PERIOD OF REPORT: 20230519 ITEM INFORMATION: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year ITEM INFORMATION: Submission of Matters to a Vote of Security Holders ITEM INFORMATION: Financial Statements and Exhibits FILED AS OF DATE: 20230524 DATE AS OF CHANGE: 20230524 FILER: COMPANY DATA: COMPANY CONFORMED NAME: CORCEPT THERAPEUTICS INC CENTRAL INDEX KEY: 0001088856 STANDARD INDUSTRIAL CLASSIFICATION: PHARMACEUTICAL PREPARATIONS [2834] IRS NUMBER: 770487658 STATE OF INCORPORATION: DE FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 8-K SEC ACT: 1934 Act SEC FILE NUMBER: 000-50679 FILM NUMBER: 23954152 BUSINESS ADDRESS: STREET 1: 149 COMMONWEALTH DRIVE CITY: MENLO PARK STATE: CA ZIP: 94025 BUSINESS PHONE: 650.688.8803 MAIL ADDRESS: STREET 1: 149 COMMONWEALTH DRIVE CITY: MENLO PARK STATE: CA ZIP: 94025 8-K 1 cort-20230519.htm 8-K cort-20230519
0001088856false12/3100010888562023-05-192023-05-19

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 OR 15(d) of the Securities Exchange Act of 1934
May 19, 2023
Date of Report (date of earliest event reported)
Corcept Therapeutics Incorporated
(Exact name of registrant as specified in its charter)
Delaware
000-50679
77-0487658
(State or other jurisdiction of incorporation or organization)
(Commission File Number)
(I.R.S. Employer Identification No.)
149 Commonwealth Drive, Menlo Park, CA 94025
(Address of Principal Executive Offices) (Zip Code)
(650) 327-3270
Registrant's telephone number, including area code
Not Applicable
(Former name or former address, if changed since last report.)
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions (see General Instruction A.2. below):
☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each classTrading Symbol(s)Name of each exchange on which registered
Common Stock, $0.001 par valueCORTThe Nasdaq Stock Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.
Emerging growth company ☐
If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.
☐


Item 5.03. Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year

At the 2023 annual meeting of stockholders of Corcept Therapeutics Incorporated (the “Company”) held on May 19, 2023 (the “Annual Meeting”), the Company’s stockholders approved an amendment and restatement of the Company’s Amended and Restated Certificate of Incorporation (the “ Restated Certificate of Incorporation”) to reflect Delaware law provisions allowing officer exculpation. The Restated Certification of Incorporation was filed with the Secretary of State of the State of Delaware on May 22, 2023. A copy of the Restated Certificate of Incorporation is attached to this Current Report on Form 8-K as Exhibit 3.1 and is incorporated herein by reference.

Item 5.07. Submission of Matters to a Vote of Security Holders
On May 19, 2023, the Company held the Annual Meeting to consider and vote on the following proposals: 1) to elect nine directors to hold office until our 2024 annual meeting of stockholders, 2) to ratify the appointment of Ernst & Young LLP as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2023, 3) to approve, on an advisory basis, the compensation of the Company's named executive officers, 4) to recommend, by non-binding advisory vote, the frequency of the advisory vote on the compensation of the Company's named executive officers, and 5) to approve the amendment and restatement of the Company's Amended and Restated Certificate of Incorporation to reflect Delaware law provisions allowing officer exculpation.
A total of 102,207,236 shares of the Company's common stock held by stockholders of record at the close of business on April 6, 2023 were entitled to vote at the Annual Meeting. The total number of shares voted at the Annual Meeting was 89,994,463. The voting on the five matters is set forth below:
Proposal 1 — Election of Directors. The following directors were elected to serve until the Company's 2024 annual meeting of stockholders.
DirectorForWithheldBroker Non-Votes
Gregg Alton68,542,3692,239,02519,213,069
G. Leonard Baker, Jr.66,577,3554,204,03919,213,069
Joseph K. Belanoff, M.D.70,198,149583,24519,213,069
Gillian M. Cannon, Ph.D.68,240,5722,540,82219,213,069
David L. Mahoney68,932,2611,849,13319,213,069
Joshua M. Murray70,337,272444,12219,213,069
Kimberly Park63,533,5897,247,80519,213,069
Daniel N. Swisher, Jr.67,206,9943,574,40019,213,069
James N. Wilson66,198,8884,582,50619,213,069
Proposal 2 — The appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2023 was ratified.
For88,986,042
Against923,595
Abstain84,826
Broker Non-Votes
Proposal 3 — Advisory vote to approve the compensation of named executive officers.
For69,095,025
Against1,450,799
Abstain235,570
Broker Non-Votes19,213,069
Proposal 4 — Advisory vote on the frequency of the vote on compensation of named executive officers.


3 years28,623,378 
2 years127,477 
1 year41,624,266 
Abstain406,273 
Broker Non-Votes19,213,069 
The Company's Board of Directors determined that the Company will hold an advisory vote on compensation of our named executive officers every year until the next frequency advisory vote, which is scheduled to be held no later than the Company's 2029 annual meeting of stockholders.
Proposal 5 — The amendment and restatement of the Company's Amended and Restated Certificate of Incorporation to reflect Delaware law provisions allowing officer exculpation was approved.
For62,951,214
Against7,616,002
Abstain214,178
Broker Non-Votes19,213,069

Item 9.01.    Financial Statements and Exhibits

(d) Exhibits
Exhibits No.Description
3.1
104Cover Page Interactive Data File (embedded within the Inline XBRL document)
         
         


SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
CORCEPT THERAPEUTICS INCORPORATED


Date:May 24, 2023By:/s/ Atabak Mokari
Name: Atabak Mokari
Title: Chief Financial Officer and Treasurer

 EX-3.1 2 a31restatedcertificateofin.htm EX-3.1 Document

Exhibit 3.1



AMENDED AND RESTATED
CERTIFICATE OF INCORPORATION
CORCEPT THERAPEUTICS INCORPORATED

Corcept Therapeutics Incorporated, a corporation organized and existing under the laws of the State of Delaware (the “Corporation”), hereby certifies as follows:

a. The name of the Corporation is Corcept Therapeutics Incorporated. The original Certificate of Incorporation was filed with the Secretary of State of the State of Delaware on May 13, 1998, and a Certificate of Designations, Preferences and Rights of Series A Preferred Stock was filed with the Secretary of State of the State of Delaware on May 26, 1999.

b. This Amended and Restated Certificate of Incorporation amends, restates, and integrates the provisions of the Amended and Restated Certificate of Incorporation filed with the Secretary of State of the State of Delaware on May 7, 2001, as amended by the Certificate of Amendment of Amended and Restated Certificate of Incorporation filed with the Secretary of State of the State of Delaware on December 18, 2002.

c. This Amended and Restated Certificate of Incorporation was duly adopted in accordance with Sections 242 and 245 of the General Corporation Law of the State of Delaware (the “DGCL”), and has been duly approved by the written consent of the stockholders of the Corporation in accordance with Section 228 of the DGCL.

d. The text of the Certificate of Incorporation of this Corporation is hereby amended and restated to read in its entirety as follows:
FIRST

The name of the Corporation is Corcept Therapeutics Incorporated.

SECOND

The address of the registered office of the Corporation in the State of Delaware is 1209 Orange Street, Corporation Trust Center, City of Wilmington, County of New Castle, Delaware 19801. The name of its registered agent at such address is The Corporation Trust Company.

THIRD

The purpose of the Corporation is to engage in any lawful act or activity for which a corporation may be organized under the Delaware General Corporation Law.

FOURTH

A.The total number of shares of all classes of stock which the Corporation shall have authority to issue is Two Hundred Ninety Million (290,000,000), consisting of Two Hundred Eighty Million (280,000,000) shares of common stock, par value $0.001 per share (the “Common Stock”), and Ten Million (10,000,000) shares of Preferred Stock, par value $0.001 per share (the “Preferred Stock”).

B.The board of directors is authorized, subject to any limitations prescribed by law, to provide for the issuance of shares of Preferred Stock in one or more series, and by filing a certificate pursuant to the applicable law of the State of Delaware (such certificate being hereinafter referred to as a “Preferred Stock Designation”), to establish from time to time the number of shares to be included in each such series, and to fix the designation, powers,


preferences, and rights of the shares of each such series and any qualifications, limitations or restrictions thereof. The number of authorized shares of Preferred Stock may be increased or decreased (but not below the number of shares thereof then outstanding) by the affirmative vote of the holders of a majority of the Common Stock, without a vote of the holders of the Preferred Stock, or of any series thereof, unless a vote of any such holders is required pursuant to the terms of any Preferred Stock Designation.

C.Each outstanding share of Common Stock shall entitle the holder thereof to one vote on each matter properly submitted to the stockholders of the Corporation for their vote; provided, however, that, except as otherwise required by law, holders of Common Stock shall not be entitled to vote on any amendment to this Certificate of Incorporation (including any Certificate of Designations relating to any series of Preferred Stock) that relates solely to the terms of one or more outstanding series of Preferred Stock if the holders of such affected series are entitled, either separately or together as a class with the holders of one or more other such series, to vote thereon by law or pursuant to this Certificate of Incorporation (including any Certificate of Designations relating to any series of Preferred Stock).

FIFTH

The following provisions are inserted for the management of the business and the conduct of the affairs of the Corporation, and for further definition, limitation and regulation of the powers of the Corporation and of its directors and stockholders:

A.The business and affairs of the Corporation shall be managed by or under the direction of the board of directors. In addition to the powers and authority expressly conferred upon them by statute or by this Certificate of Incorporation or the bylaws of the Corporation, the directors are hereby empowered to exercise all such powers and do all such acts and things as may be exercised or done by the Corporation.

B.The directors of the Corporation need not be elected by written ballot unless the bylaws so provide.

C.Any action required or permitted to be taken by the stockholders of the Corporation must be effected at a duly called annual or special meeting of stockholders of the Corporation and may not be effected by any consent in writing by such stockholders.

D.Special meetings of stockholders of the Corporation may be called only by the Chairman of the Board or the President or by the board of directors acting pursuant to a resolution adopted by a majority of the Whole Board. For purposes of this Certificate of Incorporation, the term “Whole Board” shall mean the total number of authorized directors whether or not there exist any vacancies in previously authorized directorships.

SIXTH

A.Subject to the rights of the holders of any series of Preferred Stock to elect additional directors under specified circumstances, the number of directors shall be fixed from time to time exclusively by the board of directors pursuant to a resolution adopted by a majority of the Whole Board. At each annual meeting of stockholders, directors elected to succeed those directors whose terms expire shall be elected for a term of office to expire at the succeeding annual meeting of stockholders after their election, with each director to hold office until his or her successor shall have been duly elected and qualified.

B.Subject to the rights of the holders of any series of Preferred Stock then outstanding, newly created directorships resulting from any increase in the authorized number of directors or any vacancies in the board of directors resulting from death, resignation, retirement, disqualification, removal from office or other cause shall, unless otherwise required by law or by resolution of the board of directors, be filled only by a majority vote of the directors then in office, though less than a quorum (and not by stockholders), and directors so chosen shall serve for a term expiring at the next annual meeting of stockholders or until such director’s successor shall have been duly elected and qualified. No decrease in the authorized number of directors shall shorten the term of any incumbent director.



C.Advance notice of stockholder nominations for the election of directors and of business to be brought by stockholders before any meeting of the stockholders of the Corporation shall be given in the manner provided in the bylaws of the Corporation.

SEVENTH

The board of directors is expressly empowered to adopt, amend or repeal the bylaws of the Corporation. Any adoption, amendment or repeal of the bylaws of the Corporation by the board of directors shall require the approval of a majority of the Whole Board. The stockholders shall also have power to adopt, amend or repeal the bylaws of the Corporation; provided, however, that, in addition to any vote of the holders of any class or series of stock of the Corporation required by law or by this Certificate of Incorporation, the affirmative vote of the holders of at least Sixty Six and Two Thirds percent (66 2/3%) of the voting power of all of the then-outstanding shares of the capital stock of the Corporation entitled to vote generally in the election of directors, voting together as a single class, shall be required for the stockholders to adopt, amend or repeal any provision of the bylaws of the Corporation.

EIGHTH

A director or officer of the Corporation shall not be personally liable to the Corporation or its stockholders for monetary damages for breach of fiduciary duty as a director or officer, except for liability (i) for any breach of the director’s or officer’s duty of loyalty to the Corporation or its stockholders, (ii) for acts or omissions not in good faith or which involve intentional misconduct or a knowing violation of law, (iii) with respect to a director, under Section 174 of the Delaware General Corporation Law, or (iv) for any transaction from which the director or officer derived an improper personal benefit. If the Delaware General Corporation Law is amended to authorize corporate action further eliminating or limiting the personal liability of directors or officers, then the liability of a director or officer of the Corporation shall be eliminated or limited to the fullest extent permitted by the Delaware General Corporation Law, as so amended.

Any repeal or modification of the foregoing paragraph by the stockholders of the Corporation shall not adversely affect any right or protection of a director or officer of the Corporation existing at the time of such repeal or modification.

NINTH

The Corporation reserves the right to amend or repeal any provision contained in this Certificate of Incorporation in the manner now or hereafter prescribed by the laws of the State of Delaware and all rights conferred upon stockholders are granted subject to this reservation.

IN WITNESS WHEREOF, Corcept Therapeutics Incorporated. has caused this Amended and Restated Certificate of Incorporation to be signed by a duly authorized officer of the Corporation on this 22nd day of May, 2023.


By :
/s/ G. Charles Robb
Name: G. Charles Robb
Chief Business Officer


 EX-101.SCH 3 cort-20230519.xsd XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT 0000001 - Document - Cover Page Document link:presentationLink link:calculationLink link:definitionLink EX-101.LAB 4 cort-20230519_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT Entity Central Index Key Entity Central Index Key Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address, Address Line One Trading Symbol Trading Symbol Entity Information, Former Legal or Registered Name Entity Information, Former Legal or Registered Name Entity File Number Entity File Number Pre-commencement Issuer Tender Offer Pre-commencement Issuer Tender Offer Soliciting Material Soliciting Material Entity Address, City or Town Entity Address, City or Town Entity Incorporation, State or Country Code Entity Incorporation, State or Country Code Local Phone Number Local Phone Number Entity Address, Postal Zip Code Entity Address, Postal Zip Code Written Communications Written Communications City Area Code City Area Code Cover [Abstract] Cover [Abstract] Title of 12(b) Security Title of 12(b) Security Document Type Document Type Amendment Flag Amendment Flag Current Fiscal Year End Date Current Fiscal Year End Date Security Exchange Name Security Exchange Name Entity Registrant Name Entity Registrant Name Entity Emerging Growth Company Entity Emerging Growth Company Entity Address, State or Province Entity Address, State or Province Document Period End Date Document Period End Date Pre-commencement Tender Offer Pre-commencement Tender Offer EX-101.PRE 5 cort-20230519_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT XML 6 R1.htm IDEA: XBRL DOCUMENT v3.23.1
Cover Page Document
May 19, 2023
Cover [Abstract]  
Document Type 8-K
Document Period End Date May 19, 2023
Entity Registrant Name Corcept Therapeutics Incorporated
Entity Incorporation, State or Country Code DE
Entity File Number 000-50679
Entity Tax Identification Number 77-0487658
Entity Address, Address Line One 149 Commonwealth Drive
Entity Address, City or Town Menlo Park
Entity Address, State or Province CA
Entity Address, Postal Zip Code 94025
City Area Code 650
Local Phone Number 327-3270
Entity Information, Former Legal or Registered Name Not Applicable
Written Communications false
Soliciting Material false
Pre-commencement Tender Offer false
Pre-commencement Issuer Tender Offer false
Title of 12(b) Security Common Stock, $0.001 par value
Trading Symbol CORT
Security Exchange Name NASDAQ
Entity Emerging Growth Company false
Entity Central Index Key 0001088856
Amendment Flag false
Current Fiscal Year End Date --12-31
XML 7 cort-20230519_htm.xml IDEA: XBRL DOCUMENT 0001088856 2023-05-19 2023-05-19 0001088856 false --12-31 8-K 2023-05-19 Corcept Therapeutics Incorporated DE 000-50679 77-0487658 149 Commonwealth Drive Menlo Park CA 94025 650 327-3270 Not Applicable false false false false Common Stock, $0.001 par value CORT NASDAQ false EXCEL 8 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 9 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 10 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 11 FilingSummary.xml IDEA: XBRL DOCUMENT 3.23.1 html 1 24 1 false 0 0 false 0 false false R1.htm 0000001 - Document - Cover Page Document Sheet http://www.corcept.com/role/CoverPageDocument Cover Page Document Cover 1 false false All Reports Book All Reports cort-20230519.htm a31restatedcertificateofin.htm cort-20230519.xsd cort-20230519_lab.xml cort-20230519_pre.xml http://xbrl.sec.gov/dei/2022 true false JSON 13 MetaLinks.json IDEA: XBRL DOCUMENT { "instance": { "cort-20230519.htm": { "axisCustom": 0, "axisStandard": 0, "baseTaxonomies": { "http://xbrl.sec.gov/dei/2022": 24 }, "contextCount": 1, "dts": { "inline": { "local": [ "cort-20230519.htm" ] }, "labelLink": { "local": [ "cort-20230519_lab.xml" ] }, "presentationLink": { "local": [ "cort-20230519_pre.xml" ] }, "schema": { "local": [ "cort-20230519.xsd" ], "remote": [ "http://www.xbrl.org/2003/xbrl-instance-2003-12-31.xsd", "http://www.xbrl.org/2003/xbrl-linkbase-2003-12-31.xsd", "http://www.xbrl.org/2003/xl-2003-12-31.xsd", "http://www.xbrl.org/2003/xlink-2003-12-31.xsd", "http://www.xbrl.org/2005/xbrldt-2005.xsd", "http://www.xbrl.org/lrr/role/negated-2009-12-16.xsd", "http://www.xbrl.org/lrr/role/net-2009-12-16.xsd", "https://www.xbrl.org/dtr/type/2020-01-21/types.xsd", "https://xbrl.sec.gov/dei/2022/dei-2022.xsd" ] } }, "elementCount": 25, "entityCount": 1, "hidden": { "http://xbrl.sec.gov/dei/2022": 3, "total": 3 }, "keyCustom": 0, "keyStandard": 24, "memberCustom": 0, "memberStandard": 0, "nsprefix": "cort", "nsuri": "http://www.corcept.com/20230519", "report": { "R1": { "firstAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "cort-20230519.htm", "contextRef": "iaf55941e29f04dbd96258ebb4b7716c1_D20230519-20230519", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" }, "groupType": "document", "isDefault": "true", "longName": "0000001 - Document - Cover Page Document", "menuCat": "Cover", "order": "1", "role": "http://www.corcept.com/role/CoverPageDocument", "shortName": "Cover Page Document", "subGroupType": "", "uniqueAnchor": { "ancestors": [ "span", "div", "body", "html" ], "baseRef": "cort-20230519.htm", "contextRef": "iaf55941e29f04dbd96258ebb4b7716c1_D20230519-20230519", "decimals": null, "first": true, "lang": "en-US", "name": "dei:DocumentType", "reportCount": 1, "unique": true, "unitRef": null, "xsiNil": "false" } } }, "segmentCount": 0, "tag": { "dei_AmendmentFlag": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.", "label": "Amendment Flag", "terseLabel": "Amendment Flag" } } }, "localname": "AmendmentFlag", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.corcept.com/role/CoverPageDocument" ], "xbrltype": "booleanItemType" }, "dei_CityAreaCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Area code of city", "label": "City Area Code", "terseLabel": "City Area Code" } } }, "localname": "CityAreaCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.corcept.com/role/CoverPageDocument" ], "xbrltype": "normalizedStringItemType" }, "dei_CoverAbstract": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Cover page.", "label": "Cover [Abstract]", "terseLabel": "Cover [Abstract]" } } }, "localname": "CoverAbstract", "nsuri": "http://xbrl.sec.gov/dei/2022", "xbrltype": "stringItemType" }, "dei_CurrentFiscalYearEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "End date of current fiscal year in the format --MM-DD.", "label": "Current Fiscal Year End Date", "terseLabel": "Current Fiscal Year End Date" } } }, "localname": "CurrentFiscalYearEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.corcept.com/role/CoverPageDocument" ], "xbrltype": "gMonthDayItemType" }, "dei_DocumentPeriodEndDate": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "For the EDGAR submission types of Form 8-K: the date of the report, the date of the earliest event reported; for the EDGAR submission types of Form N-1A: the filing date; for all other submission types: the end of the reporting or transition period. The format of the date is YYYY-MM-DD.", "label": "Document Period End Date", "terseLabel": "Document Period End Date" } } }, "localname": "DocumentPeriodEndDate", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.corcept.com/role/CoverPageDocument" ], "xbrltype": "dateItemType" }, "dei_DocumentType": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.", "label": "Document Type", "terseLabel": "Document Type" } } }, "localname": "DocumentType", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.corcept.com/role/CoverPageDocument" ], "xbrltype": "submissionTypeItemType" }, "dei_EntityAddressAddressLine1": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Address Line 1 such as Attn, Building Name, Street Name", "label": "Entity Address, Address Line One", "terseLabel": "Entity Address, Address Line One" } } }, "localname": "EntityAddressAddressLine1", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.corcept.com/role/CoverPageDocument" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressCityOrTown": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the City or Town", "label": "Entity Address, City or Town", "terseLabel": "Entity Address, City or Town" } } }, "localname": "EntityAddressCityOrTown", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.corcept.com/role/CoverPageDocument" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressPostalZipCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Code for the postal or zip code", "label": "Entity Address, Postal Zip Code", "terseLabel": "Entity Address, Postal Zip Code" } } }, "localname": "EntityAddressPostalZipCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.corcept.com/role/CoverPageDocument" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityAddressStateOrProvince": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Name of the state or province.", "label": "Entity Address, State or Province", "terseLabel": "Entity Address, State or Province" } } }, "localname": "EntityAddressStateOrProvince", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.corcept.com/role/CoverPageDocument" ], "xbrltype": "stateOrProvinceItemType" }, "dei_EntityCentralIndexKey": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.", "label": "Entity Central Index Key", "terseLabel": "Entity Central Index Key" } } }, "localname": "EntityCentralIndexKey", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.corcept.com/role/CoverPageDocument" ], "xbrltype": "centralIndexKeyItemType" }, "dei_EntityEmergingGrowthCompany": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "Indicate if registrant meets the emerging growth company criteria.", "label": "Entity Emerging Growth Company", "terseLabel": "Entity Emerging Growth Company" } } }, "localname": "EntityEmergingGrowthCompany", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.corcept.com/role/CoverPageDocument" ], "xbrltype": "booleanItemType" }, "dei_EntityFileNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.", "label": "Entity File Number", "terseLabel": "Entity File Number" } } }, "localname": "EntityFileNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.corcept.com/role/CoverPageDocument" ], "xbrltype": "fileNumberItemType" }, "dei_EntityIncorporationStateCountryCode": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Two-character EDGAR code representing the state or country of incorporation.", "label": "Entity Incorporation, State or Country Code", "terseLabel": "Entity Incorporation, State or Country Code" } } }, "localname": "EntityIncorporationStateCountryCode", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.corcept.com/role/CoverPageDocument" ], "xbrltype": "edgarStateCountryItemType" }, "dei_EntityInformationFormerLegalOrRegisteredName": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Former Legal or Registered Name of an entity", "label": "Entity Information, Former Legal or Registered Name", "terseLabel": "Entity Information, Former Legal or Registered Name" } } }, "localname": "EntityInformationFormerLegalOrRegisteredName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.corcept.com/role/CoverPageDocument" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityRegistrantName": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.", "label": "Entity Registrant Name", "terseLabel": "Entity Registrant Name" } } }, "localname": "EntityRegistrantName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.corcept.com/role/CoverPageDocument" ], "xbrltype": "normalizedStringItemType" }, "dei_EntityTaxIdentificationNumber": { "auth_ref": [ "r1" ], "lang": { "en-us": { "role": { "documentation": "The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.", "label": "Entity Tax Identification Number", "terseLabel": "Entity Tax Identification Number" } } }, "localname": "EntityTaxIdentificationNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.corcept.com/role/CoverPageDocument" ], "xbrltype": "employerIdItemType" }, "dei_LocalPhoneNumber": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Local phone number for entity.", "label": "Local Phone Number", "terseLabel": "Local Phone Number" } } }, "localname": "LocalPhoneNumber", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.corcept.com/role/CoverPageDocument" ], "xbrltype": "normalizedStringItemType" }, "dei_PreCommencementIssuerTenderOffer": { "auth_ref": [ "r3" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act.", "label": "Pre-commencement Issuer Tender Offer", "terseLabel": "Pre-commencement Issuer Tender Offer" } } }, "localname": "PreCommencementIssuerTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.corcept.com/role/CoverPageDocument" ], "xbrltype": "booleanItemType" }, "dei_PreCommencementTenderOffer": { "auth_ref": [ "r4" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act.", "label": "Pre-commencement Tender Offer", "terseLabel": "Pre-commencement Tender Offer" } } }, "localname": "PreCommencementTenderOffer", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.corcept.com/role/CoverPageDocument" ], "xbrltype": "booleanItemType" }, "dei_Security12bTitle": { "auth_ref": [ "r0" ], "lang": { "en-us": { "role": { "documentation": "Title of a 12(b) registered security.", "label": "Title of 12(b) Security", "terseLabel": "Title of 12(b) Security" } } }, "localname": "Security12bTitle", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.corcept.com/role/CoverPageDocument" ], "xbrltype": "securityTitleItemType" }, "dei_SecurityExchangeName": { "auth_ref": [ "r2" ], "lang": { "en-us": { "role": { "documentation": "Name of the Exchange on which a security is registered.", "label": "Security Exchange Name", "terseLabel": "Security Exchange Name" } } }, "localname": "SecurityExchangeName", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.corcept.com/role/CoverPageDocument" ], "xbrltype": "edgarExchangeCodeItemType" }, "dei_SolicitingMaterial": { "auth_ref": [ "r5" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as soliciting material pursuant to Rule 14a-12 under the Exchange Act.", "label": "Soliciting Material", "terseLabel": "Soliciting Material" } } }, "localname": "SolicitingMaterial", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.corcept.com/role/CoverPageDocument" ], "xbrltype": "booleanItemType" }, "dei_TradingSymbol": { "auth_ref": [], "lang": { "en-us": { "role": { "documentation": "Trading symbol of an instrument as listed on an exchange.", "label": "Trading Symbol", "terseLabel": "Trading Symbol" } } }, "localname": "TradingSymbol", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.corcept.com/role/CoverPageDocument" ], "xbrltype": "tradingSymbolItemType" }, "dei_WrittenCommunications": { "auth_ref": [ "r6" ], "lang": { "en-us": { "role": { "documentation": "Boolean flag that is true when the Form 8-K filing is intended to satisfy the filing obligation of the registrant as written communications pursuant to Rule 425 under the Securities Act.", "label": "Written Communications", "terseLabel": "Written Communications" } } }, "localname": "WrittenCommunications", "nsuri": "http://xbrl.sec.gov/dei/2022", "presentation": [ "http://www.corcept.com/role/CoverPageDocument" ], "xbrltype": "booleanItemType" } }, "unitCount": 0 } }, "std_ref": { "r0": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r1": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "b-2", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r2": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "12", "Subsection": "d1-1", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r3": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "13e", "Subsection": "4c", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r4": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14d", "Subsection": "2b", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r5": { "Name": "Exchange Act", "Number": "240", "Publisher": "SEC", "Section": "14a", "Subsection": "12", "role": "http://www.xbrl.org/2003/role/presentationRef" }, "r6": { "Name": "Securities Act", "Number": "230", "Publisher": "SEC", "Section": "425", "role": "http://www.xbrl.org/2003/role/presentationRef" } }, "version": "2.2" } ZIP 14 0001628280-23-019588-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001628280-23-019588-xbrl.zip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